Navigation Links
Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
Date:9/19/2012

OKLAHOMA CITY, Sept. 19, 2012 /PRNewswire/ -- Selexys Pharmaceuticals, Corp., announced today that it has successfully completed a $23 million Series A equity financing, led by MPM Capital.  Additionally, Selexys entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell disease.  Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $665 million.

The Series A financing includes a new major investor, MPM Capital. Concurrent with the investment, Selexys also announced the addition of Todd Foley, Managing Director of MPM Capital, to the Selexys Pharmaceuticals Board of Directors.

"Patients with sickle cell disease endure great suffering and frequent hospitalization due to painful vasoocclusive crises. Chronic blockade of P-selectin function with SelG1 may improve clinical outcomes and lower the associated cost of patient care," said Dr. Scott Rollins, President and CEO of Selexys. "We are excited to welcome MPM and Novartis and look forward to a productive partnership." The combination of the Novartis agreement and the closing of the Series A financing will allow Selexys to advance the SelG1 program through a large Phase 2 clinical study in sickle cell patients and will also fund a second program at Selexys, an anti-PSGL-1 antibody, through a Phase I clinical study.

"Vasoocculsive crises represent a significant healthcare problem for sickle cell disease patients, and we were impressed by the early data for SelG1 and the quality of the Selexys team," said Todd Foley, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Selexys."

About SelG1

SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. In preclinical studies, inhibition of P-selectin has been shown to effectively prevent vasoocclusion by blocking critical cell-cell interactions that drive this process. Therapeutic blockade of P-selectin may therefore reduce or prevent vasoocclusive crises in patients with sickle cell disease.

"SelG1 is a first-in-class therapeutic approach for the treatment of vasoocclusive crisis in sickle cell disease," stated Dr. Russell Rother, Selexys Executive Vice-president and COO. "Results from the recently completed Phase I safety study indicate that SelG1 is safe and well tolerated in healthy human subjects, and we are now eager to investigate its safety and efficacy in the sickle cell disease patient population."

The SelG1 program for sickle cell disease is supported by Small Business Innovation Research (SBIR) fast-track award #5R44HL093893-02 and #2R44HL093893-03 through the National Heart, Lung and Blood Institute.

About Selexys Pharmaceuticals

Selexys Pharmaceuticals, Corp., is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation, thrombosis and metastasis across a broad range of severe diseases.  Selexys is also developing an antibody directed against PSGL-1 for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders. Selexys is headquartered in Oklahoma City, OK.  For additional information please visit our website at www.selexys.com.

About MPM Capital

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.6 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.


'/>"/>
SOURCE Selexys Pharmaceuticals, Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
Breaking Medicine News(10 mins):